•Submitted articles must not be longer than 2,500 words and have no more than 10 display items (e.g. figures, tables etc.)
•Submissions must be relevant to the field of SCI.
•Submissions can be old research but must contribute a new ‘lesson learned’ to the field of SCI
•Any of a ResearchGate publication’s authors can submit an entry into the prize on behalf of their co-authors but they must ensure they have been granted permission to do so.
So that reviewers understand this is not a typical ResearchGate publication, all entries will be required to submit a short paragraph at the beginning of their article, outlining the fact that their research is being submitted into the Trial & Error prize. ResearchGate users should understand this when reviewing their document. The paragraph should be worded as follows:
This research is being entered into the Conquer Paralysis Now Trial & Error Prize, which aims to gather lessons learned from Spinal Cord Injury Research, and foster open discourse within the SCI community. Please bear this in mind while reviewing this publication. This article is simply meant to provide others with information that can help them in future trials or research. By entering the Prize, the authors hereby agree to its term and conditions as outlined here.
When reviewing, please take into account the judging criteria below for this prize:
Articles must also include:
•A short abstract designed to summarize the main topics and essential findings of the research
•Up to six short words or phrases, which best describe your research. These will be used to index your article
The introduction should be concise and not contain subheadings. It should only provide necessary background information, rather than a comprehensive review of your research.
Materials and Methods: This section should contain enough detail so that all experimental procedures can be repeated by others. Authors should provide the name of the manufacturer and their location for any specific medical equipment, and all drugs should be identified by their pharmaceutical names, and not by their trade name.
Results and Discussion: The results should briefly present the experimental data. The data in tables and figures should not be described in detail in the text. The Discussion should not repeat information from the Results. It should focus on the significance and interpretation of the findings with objective comments that describe their relation to other work in the field. It should not repeat information in the Results.
References: References should be listed in the order in which they are cited in the text. Only published works and manuscripts should be listed in the reference list.